BRAF
Serine/threonine-protein kinase B-raf
Protein Summary
Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway. This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this g ...more
- ENST00000646891
- ENSP00000493543
- ENSG00000157764
- BRAF1
- RAFB1
- NS7
- B-raf
- BRAF1
- RAFB1
- B-RAF1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological process | 1 | ||
molecular function | 1 | ||
hub protein | 0.99 | ||
protein domain | 0.99 | ||
transcription factor perturbation | 0.99 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 646.73 (req: < 5)
Gene RIFs: 2473 (req: <= 3)
Antibodies: 2018 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 646.73 (req: >= 5)
Gene RIFs: 2473 (req: > 3)
Antibodies: 2018 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 45
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2025
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 6